Abstract 1740P
Background
About 55% of the population worldwide lives in urban areas, and agreeing to WHO (World Health Organization), 91% of people in cities do not breathe safe air. There is evidence of a positive correlation between PM2.5 and lung cancer mortality. The Metropolitan Area of Monterrey, México, is the country's third most significant and most polluted, with an annual average of 23 μg/m3 PM2.5, equivalent to 2.3 times the value established by the WHO. Objective. This study aimed to identify if spatial exposure patterns to PM2.5 correlate to respiratory tract cancer incidence.
Methods
Daily concentrations of PM2.5 were estimated considering the PM10/PM2.5 ratio in local stations that measured both fractions. Subsequently, the available fraction per station was calculated, considering the fractions of all available station data. Finally, the general fraction of the entire study period was calculated. The morbidity data for this study came from an individual-level database that contained the geographical coordinates of the residences of the airway cancer cases (bronchi, lung, larynx, and paranasal sinuses).
Results
The average concentration of PM2.5 was 32.4 μg/m3, 3.24 times the limit established by the WHO. We identified that the increase in PM levels was associated with the number of cancer cases. The mean age of the cases was 70 years. There were 76.77% (n = 476) patients with a lung cancer diagnosis, followed by laryngeal cancer at 21.77% (n = 135). Interestingly, we detect that 44.35% (n = 275) has never smoked. On the other hand, there were 44.67% (n=277) heavy smokers in the cancer cases.
Conclusions
Implementing preventive measures to reduce emissions and exposure to PM2.5 and other air pollutants in polluted cities is necessary. High concentrations of PM2.5 are related to cancer cases, and it is essential to implement preventive cancer detection measures in polluted areas, not only in smokers’ cases. In addition, spatial analyses are valuable to describe, quantify and explain the geographical variations of diseases associated with particulate matter exposure.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Centro Universitario Contra el Cancer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23